• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by Anzu Special Acquisition Corp I

    2/14/22 9:10:51 AM ET
    $ANZU
    Blank Checks
    Finance
    Get the next $ANZU alert in real time by email
    SC 13G 1 d306386dsc13g.htm SC 13G SC 13G

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    SCHEDULE 13G

    Under the Securities Exchange Act of 1934

    (Amendment No. *)

     

     

    Anzu Special Acquisition Corp. I

    (Name of Issuer)

    Class A Common Stock, par value $0.0001 per share

    (Title of Class of Securities)

    03737A101

    (CUSIP Number)

    December 31, 2021

    (Date of Event Which Requires Filing of this Statement)

     

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

      ☒

    Rule 13d-1(b)

     

      ☐

    Rule 13d-1(c)

     

      ☐

    Rule 13d-1(d)

     

    *

    The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     


    CUSIP No. 03737A101    SCHEDULE 13G    Page 2 of 5 Pages

     

      1    

      NAME OF REPORTING PERSON

     

      Aristeia Capital, L.L.C. (1)

      2  

      CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*

      (a)  ☐        (b)  ☐

     

      3  

      SEC USE ONLY

     

      4  

      CITIZENSHIP OR PLACE OF ORGANIZATION

     

      Delaware

    NUMBER OF

    SHARES

     BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

       5    

      SOLE VOTING POWER

     

      2,671,926

       6  

      SHARED VOTING POWER

     

      0

       7  

      SOLE DISPOSITIVE POWER

     

      2,671,926

       8  

      SHARED DISPOSITIVE POWER

     

      9    

      AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

      2,671,926

    10  

      CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES*

     

      ☐

    11  

      PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

     

      6.29% (2)

    12  

      TYPE OF REPORTING PERSON*

     

      IA, OO

     

    (1)

    Aristeia Capital, L.L.C. is the investment manager of, and has voting and investment control with respect to the securities described herein held by, one or more private investment funds.

    (2)

    Based on 42,500,000 shares of Class A Common Stock, par value $0.0001 per share of the Issuer outstanding as of December 30, 2021, as reported in the Issuer’s Form 10-Q/A filed with the Securities and Exchange Commission (the “SEC”) on January 3, 2022.


    CUSIP No. 03737A101    SCHEDULE 13G    Page 3 of 5 Pages

     

    Item 1(a).    Name of Issuer:
       Anzu Special Acquisition Corp. I
    Item 1(b).    Address of Issuer’s Principal Executive Offices:
      

    12610 Race Track Road, Suite 250

    Tampa, Florida 33626

    Item 2(a).    Name of Person Filing.
    Item 2(b).    Address of Principal Business Office or, if None, Residence.
    Item 2(c).    Citizenship.
      

    Aristeia Capital, L.L.C.

    One Greenwich Plaza, 3rd Floor

    Greenwich, CT 06830

    Delaware limited liability company

    Item 2(d).    Title of Class of Securities:
       Class A Common Stock, par value $0.0001 per share
    Item 2(e).    CUSIP Number:
       03737A101
    Item 3.    If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
       ☒   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E).
    Item 4.    Ownership.
      

    The following is information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1 as of 12/31/2021.

    Items 5-9 and 11 of the cover page to this Schedule 13G are incorporated herein by reference. :

       (a)    Amount beneficially owned: 2,671,926
       (b)    Percent of Class: 6.29%
       (c)    Number of shares as to which such person has:
          (i)    sole power to vote or direct the vote: 2,671,926
          (ii)    shared power to vote or direct the vote: 0


    CUSIP No. 03737A101    SCHEDULE 13G    Page 4 of 5 Pages

     

          (iii)    sole power to dispose or direct the disposition of: 2,671,926
          (iv)    shared power to dispose or direct the disposition of: 0
    Item 5.    Ownership of Five Percent or Less of a Class.
       If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following  ☐
    Item 6.    Ownership of More than Five Percent on Behalf of Another Person.
       Not Applicable
    Item 7.    Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company.
       Not Applicable
    Item 8.    Identification and Classification of Members of the Group.
       Not Applicable
    Item 9.    Notice of Dissolution of Group.
       Not Applicable
    Item 10.    Certification.
       Certification pursuant to §240.13d-1(b):
       By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.


    CUSIP No. 03737A101    SCHEDULE 13G    Page 5 of 5 Pages

     

    SIGNATURE

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    Dated: 2/14/2022

     

    ARISTEIA CAPITAL, L.L.C.
    By:  

    /s/ Andrew B. David

      Name: Andrew B. David
      Title: Chief Operating Officer
    Get the next $ANZU alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ANZU

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $ANZU
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Anzu Special Acquisition Corp I Stockholders Approve Business Combination with Envoy Medical Corporation

    Anzu Special Acquisition Corp I (the "Company") (NASDAQ: "ANZU," "ANZUU" and "ANZUW"), announced today that its stockholders voted to approve the Business Combination Agreement with Envoy Medical Corporation ("Envoy"), and the transactions contemplated thereby (the "Business Combination") at the Company's special meeting of stockholders held on September 27, 2023 (the "Special Meeting"). Pursuant to the Business Combination Agreement, Merger Sub will merge with and into Envoy, with Envoy surviving the merger as a wholly owned subsidiary of the Company (the "Merger"). Following the closing of the Merger (the "Closing"), the Company will be renamed "Envoy Medical, Inc.", which is referred t

    9/27/23 4:10:00 PM ET
    $ANZU
    Blank Checks
    Finance

    Anzu Special Acquisition Corp I Announces Adjournment of Special Meeting of Stockholders

    Anzu Special Acquisition Corp I (the "Company") (NASDAQ: "ANZU," "ANZUU" and "ANZUWS"), announced today that it convened and then adjourned, without conducting any other business, the Company's special meeting of stockholders (the "Special Meeting") held on February 9, 2023. The Special Meeting has been adjourned until 9:30 a.m., Eastern time, on February 21, 2023 (the "Adjourned Special Meeting"). The Adjourned Special Meeting will be held virtually via live webcast at https://web.lumiagm.com/274911563. The record date remains the close of business, Eastern Time, on January 17, 2023. At the Adjourned Special Meeting, stockholders will be asked to vote on a proposal to amend the Company's

    2/9/23 4:15:00 PM ET
    $ANZU
    Blank Checks
    Finance

    $ANZU
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Lucas Brent T. bought $11,990 worth of shares (12,380 units at $0.97), increasing direct ownership by 11% to 120,831 units (SEC Form 4)

    4 - Envoy Medical, Inc. (0001840877) (Issuer)

    11/24/23 4:09:42 PM ET
    $ANZU
    Blank Checks
    Finance

    $ANZU
    SEC Filings

    View All

    SEC Form S-1/A filed by Anzu Special Acquisition Corp I (Amendment)

    S-1/A - Envoy Medical, Inc. (0001840877) (Filer)

    2/14/24 9:17:12 PM ET
    $ANZU
    Blank Checks
    Finance

    SEC Form S-1 filed by Anzu Special Acquisition Corp I

    S-1 - Envoy Medical, Inc. (0001840877) (Filer)

    1/18/24 5:09:23 PM ET
    $ANZU
    Blank Checks
    Finance

    SEC Form 10-Q/A filed by Anzu Special Acquisition Corp I (Amendment)

    10-Q/A - Envoy Medical, Inc. (0001840877) (Filer)

    1/17/24 4:16:52 PM ET
    $ANZU
    Blank Checks
    Finance

    $ANZU
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Taylor Glen A (Amendment)

    4/A - Envoy Medical, Inc. (0001840877) (Issuer)

    12/4/23 4:57:21 PM ET
    $ANZU
    Blank Checks
    Finance

    Lucas Brent T. bought $11,990 worth of shares (12,380 units at $0.97), increasing direct ownership by 11% to 120,831 units (SEC Form 4)

    4 - Envoy Medical, Inc. (0001840877) (Issuer)

    11/24/23 4:09:42 PM ET
    $ANZU
    Blank Checks
    Finance

    SEC Form 4 filed by Taylor Glen A

    4 - Envoy Medical, Inc. (0001840877) (Issuer)

    11/22/23 4:11:45 PM ET
    $ANZU
    Blank Checks
    Finance

    $ANZU
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Anzu Special Acquisition Corp I (Amendment)

    SC 13G/A - Envoy Medical, Inc. (0001840877) (Subject)

    2/12/24 4:30:47 PM ET
    $ANZU
    Blank Checks
    Finance

    SEC Form SC 13G/A filed by Anzu Special Acquisition Corp I (Amendment)

    SC 13G/A - Anzu Special Acquisition Corp I (0001840877) (Subject)

    2/13/23 12:29:11 PM ET
    $ANZU
    Blank Checks
    Finance

    SEC Form SC 13G filed by Anzu Special Acquisition Corp I

    SC 13G - Anzu Special Acquisition Corp I (0001840877) (Subject)

    2/14/22 2:25:31 PM ET
    $ANZU
    Blank Checks
    Finance